The collective findings on this novel Bcl-2 BH4 antagonist suggest that CYD0281 may act as a powerful pharmacological tool for further elucidating the functions of Bcl-2 and its BH domains, and also serve as a potential therapeutic drug candidate for targeting neovascularization in breast cancer. This evidence concerns the gene BCL2 and breast carcinoma.